LLY
OABI
Lilly just gave OmniAb a shiny new reason to move
OmniAb woke up with a lot more pep in its step after announcing a global collaboration and license agreement with Eli Lilly for a new ion channel program. The market did what the market does: heard “Lilly” and “milestones” in the same sentence and sent OABI jumping in premarket.
Why investors are suddenly interested
This isn’t just a science-fair handshake. Under the deal, Lilly gets access to OmniAb’s ion channel discovery and screening capabilities, while OmniAb gets the kind of economics biotech dreams are made of:
- an upfront payment, though the company didn’t say how chunky it is
- up to $370 million in research, development, and commercial milestone payments
- tiered royalties on global net sales
That’s the kind of setup that can turn a platform company from “nice story” into “maybe this thing prints cash someday.”
Cash is getting a little less awkward
OmniAb also raised its 2026 cash outlook, now expecting to finish the year with $49 million to $53 million in cash and equivalents, up from $37 million to $41 million. In biotech-land, that’s not exactly buying a private island money, but it does mean a better runway — and runway matters when you’re betting on partnerships to keep the lights on.
The stock is doing its best impression of a rocket
Shares were up 18.34% to $4.00 in premarket trading, and the move also pushed the stock to a new 52-week high. Of course, this kind of surge can get a little frothy fast: the article flagged an RSI above 80, which is basically the market’s way of saying, “Nice run, but maybe don’t get too comfortable.”
Big picture: OmniAb just landed a partnership that gives investors a real reason to watch the platform story again — not just for the science, but for the potential money trail attached to it.